|
Jun 23
|
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
|
|
Jun 21
|
Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease
|
|
Jun 20
|
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
|
|
Jun 20
|
DoH – Abu Dhabi and Sanofi link for vaccine development
|
|
Jun 20
|
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
|
|
Jun 17
|
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
|
|
Jun 17
|
Press release: Sanofi successfully prices €1.5 billion bond issue
|
|
Jun 16
|
European Equities Close Mostly Higher in Monday Trading; Renault CEO to Step Down, Expected to Join Kering
|
|
Jun 16
|
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
|
|
Jun 15
|
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
|
|
Jun 15
|
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
|
|
Jun 15
|
Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
|
|
Jun 15
|
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
|
|
Jun 12
|
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 10
|
Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand
|
|
Jun 10
|
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
|
|
Jun 9
|
Sanofi: Information concerning the total number of voting rights and shares - May 2025
|
|
Jun 9
|
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
|
|
Jun 9
|
Regeneron and Sanofi’s dupilumab shows promise in AD trial
|